References
- Jabbour E, Short NJ, Ravandi F, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol. 2018 Dec;5(12):e618–e627. doi: 10.1016/S2352-3026(18)30176-5
- Jabbour E, Short NJ, Jain N, et al. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2023 Jan;10(1):e24–e34. doi: 10.1016/S2352-3026(22)00319-2
- Foà R, Bassan R, Elia L, et al. Long-term results of the dasatinib-blinatumomab protocol for adult Philadelphia-positive ALL. J Clin Oncol. 2024 Mar 10;42(8);881–885. doi: 10.1200/JCO.23.01075
- Short NJ, Jabbour E, Albitar M, et al. Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: a consensus of North American experts. Am J Hematol. 2019 Feb;94(2):257–265. doi: 10.1002/ajh.25338
- Berry DA, Zhou S, Higley H, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Onc. 2017 Jul 13;3(7):e170580. doi: 10.1001/jamaoncol.2017.0580
- Short NJ, Jabbour E, Sasaki K, et al. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2016 Jul 28;128(4):504–507. doi: 10.1182/blood-2016-03-707562
- Sasaki K, Kantarjian HM, Short NJ, et al. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer. 2021 Aug 1;127(15):2648–2656. doi: 10.1002/cncr.33529
- Ghobadi A, Slade M, Kantarjian H, et al. The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis. Blood. 2022 Nov 17;140(20):2101–2112. doi: 10.1182/blood.2022016194
- Coccaro N, Anelli L, Zagaria A, et al. Droplet digital PCR is a robust tool for monitoring minimal residual disease in adult Philadelphia-positive acute lymphoblastic leukemia. J Mol Diagn. 2018 Jul;20(4):474–482. doi: 10.1016/j.jmoldx.2018.03.002
- Ansuinelli M, Della Starza I, Lauretti A, et al. Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia-positive acute lymphoblastic leukaemia. Hematol Oncol. 2021 Dec;39(5):680–686. doi: 10.1002/hon.2913
- Cazzaniga G, De Lorenzo P, Alten J, et al. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies. Haematologica. 2018 Jan;103(1):107–115. doi: 10.3324/haematol.2017.176917
- Hovorkova L, Zaliova M, Venn NC, et al. Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology. Blood. 2017 May 18;129(20):2771–2781. doi: 10.1182/blood-2016-11-749978
- Zuna J, Hovorkova L, Krotka J, et al. Minimal residual disease in BCR: ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease. Leukemia. 2022 Dec;36(12):2793–2801. doi: 10.1038/s41375-022-01668-0
- Short NJ, Jabbour E, Macaron W, et al. Ultrasensitive NGS MRD assessment in Ph+ ALL: prognostic impact and correlation with RT-PCR for BCR: ABL1. Am J Hematol. 2023 Aug;98(8):1196–1203. doi: 10.1002/ajh.26949
- Wood B, Wu D, Crossley B, et al. Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. Blood. 2018 Mar 22;131(12):1350–1359. doi: 10.1182/blood-2017-09-806521
- Short NJ, Kantarjian H, Ravandi F, et al. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv. 2022 Jul 12;6(13):4006–4014. doi: 10.1182/bloodadvances.2022007378
- Kotrová M, Koopmann J, Trautmann H, et al. Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methods. Blood Adv. 2022;6(10):3006–3010. doi: 10.1182/bloodadvances.2021006727